Moreover, the efficacy of THZ531 is currently being tested in an observational trial employing organoids derived from high grade serous ovarian cancer patients (NCT04555473; Table 1), to verify whether CDK12 inhibition sensitises DDR‐proficient tumours to PARPi [180]. The gene discussed is CDK12; the disease is neoplasm.